Market Overview

The Global Thyroid Gland Disorder Treatment Market is expanding as healthcare systems address the growing burden of hypothyroidism, hyperthyroidism, Graves’ disease, thyroiditis, thyroid nodules, and thyroid cancer. Treatment strategies vary according to the underlying condition and can include thyroid hormone replacement, antithyroid medicines, radioactive iodine, surgery, and disease-specific therapies. The market is also being influenced by improved screening, greater disease awareness, personalized treatment approaches, and development of new formulations. One market estimate valued the dedicated thyroid gland disorder treatment market at USD 2.39 billion in 2024 and projects it to reach USD 3.13 billion by 2031, representing a 3.9% CAGR. Broader estimates that include thyroid diagnostics alongside treatment are substantially larger, illustrating the effect of differing market definitions.

Market Value Snapshot

Metric	Market Insight
Market Size, 2024	USD 2.39 Billion
Forecast Market Size, 2031	USD 3.13 Billion
CAGR, 2025–2031	3.9%
Leading Indication	Hypothyroidism
Leading Drug	Levothyroxine
Major Route	Oral
Leading Region	North America
Fastest-Growing Region	Asia Pacific
Key Treatment Areas	Hormone Replacement & Hyperthyroidism Management

Key Market Factors

• Trend: Treatment is moving toward more patient-specific management, including liquid and gel-cap levothyroxine formulations, improved dose monitoring, digital adherence support, and individualized treatment strategies
• Driver: Rising awareness and diagnosis of thyroid disorders, autoimmune thyroid disease, aging populations, and greater access to endocrine care are expanding the treated patient population
• Challenge: Long-term medication adherence, dose adjustment, generic price competition, adverse effects associated with some therapies, and shortages of specialized endocrine-care professionals can constrain market development
• Opportunity: Personalized hormone replacement, improved drug formulations, telehealth-enabled monitoring, point-of-care testing, targeted therapies, and integrated diagnostic-treatment pathways offer opportunities for market participants

Regional Outlook

North America: North America represented the largest regional market in 2025 in one recent assessment, accounting for approximately 44.89% of revenue. The region benefits from established healthcare infrastructure, widespread thyroid testing, access to hormone replacement therapies, specialist care, and established pharmaceutical companies.

Europe: European demand is supported by established endocrine-care systems, thyroid screening and monitoring, aging demographics, autoimmune disease management, and availability of both generic and branded therapies. Healthcare providers are increasingly emphasizing long-term disease monitoring and patient-centered treatment.

Asia Pacific: Asia Pacific is expected to be the fastest-growing regional market, supported by increasing awareness, improving healthcare access, rising healthcare expenditure, and expansion of diagnostic and treatment services. Growing access to thyroid testing and pharmaceutical distribution across emerging economies is also supporting market penetration.

Latin America: Market development is supported by improving diagnostic access, expansion of retail and online pharmaceutical channels, and increasing awareness of endocrine disorders. Brazil, Mexico, and Argentina represent important markets for thyroid therapies.

Middle East & Africa: Increasing healthcare investment, improved diagnostic infrastructure, specialist-care development, and broader access to essential medicines are creating opportunities for thyroid-disorder treatment providers.

Types

• Thyroid Hormone Replacement Therapy
• Levothyroxine
• Liothyronine
• Combination T4/T3 Therapy
• Antithyroid Drugs
• Methimazole
• Propylthiouracil
• Imidazole-Based Compounds
• Radioactive Iodine Therapy
• Thyroid Surgery
• Targeted Thyroid Cancer Therapy
• Oral Therapies
• Intravenous Therapies
• Tablet Formulations
• Liquid Formulations
• Gel-Capsule Formulations

Applications

• Hypothyroidism
• Hyperthyroidism
• Graves’ Disease
• Hashimoto’s Disease
• Thyroiditis
• Toxic Thyroid Nodules
• Thyroid Nodules
• Goiter
• Thyroid Cancer
• Post-Thyroidectomy Hormone Replacement
• Radiation-Induced Hypothyroidism
• Congenital Hypothyroidism
• Pregnancy-Related Thyroid Disorders
• Pediatric Thyroid Disorders
• Long-Term Thyroid Hormone Management

Recent Activities & Developments

Levothyroxine remains central to hypothyroidism treatment. The American Thyroid Association notes that thyroid hormone replacement is used when the thyroid cannot produce sufficient hormone or has been surgically removed, with levothyroxine available in tablet, liquid, and gel-capsule formulations. Treatment requires monitoring to keep thyroid hormone levels within the patient’s target range.

For hyperthyroidism, treatment options include antithyroid drugs, radioactive iodine, and surgery, with the appropriate approach depending on the underlying disease, clinical circumstances, treatment risks, and patient preferences.

Radioactive iodine remains an important therapeutic modality. The American Thyroid Association explains that I-131 can be used to destroy overactive thyroid tissue in hyperthyroidism and can also be used in the treatment of thyroid cancer.

The market is also moving toward patient-centric formulations and treatment management. Liquid and gel-cap levothyroxine formulations can provide alternatives to conventional tablets, while improved monitoring and digital healthcare services can support medication adherence and long-term disease management.

Thyroid cancer represents another important development area. The American Thyroid Association published updated 2025 management guidelines for adult patients with differentiated thyroid cancer, reflecting continued evolution in treatment and disease-management approaches.

The competitive landscape includes AbbVie, Amgen, GSK, Merck KGaA, Viatris, Novartis, Pfizer, Takeda Pharmaceutical, IBSA Pharma, and other pharmaceutical companies involved in thyroid and endocrine therapeutics.

Going forward, the market is expected to increasingly emphasize personalized hormone replacement, improved formulations, treatment adherence, earlier diagnosis, digital monitoring, targeted thyroid-cancer therapies, and integrated endocrine-care pathways, while long-term medication management remains a core component of the global treatment landscape.